Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12912581 | 0.95 | SIRT2 (0.50) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL29992246 | 0.90 | ESR1 (0.50) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL28653866 | 0.90 | ESR1 (0.50) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL17943149 | 0.88 | ESR1 (0.49) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL18314223 | 0.88 | ESR1 (0.54) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL12912585 | 0.87 | ESR1 (0.45) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL21769826 | 0.84 | DCTPP1 (0.47) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL29991475 | 0.83 | PDE10A (0.48) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL16440841 | 0.83 | PDE10A (0.48) | ESR1ESR2SIRT2SIRT1MEN1 | |
| SCHEMBL338139 | 0.83 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1HCAR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297191-B2 | Heterocyclic derivative and organic electroluminescent device thereof | CHANGCHUN HYPERIONS TECHNOLOGY CO., LTD (CN) | 2025-05-13 | — | — | US | disclosed |
| CN-114573593-B | Dicarbazole compound, intermediate, organic electroluminescent device and display device | 阜阳欣奕华材料科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11665961-B2 | Heterocyclic compound and organic light emitting device using same | LT MATERIALS CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| US-11665961-B2 | Heterocyclic compound and organic light emitting device using same | LT MATERIALS CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| CN-113735835-B | Compound, organic electroluminescent device and display device | 阜阳欣奕华材料科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-114573593-A | Dicarbazole compound, intermediate, organic electroluminescent device and display device | 阜阳欣奕华材料科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20220173333-A1 | HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE THEREOF | CHANGCHUN HYPERIONS TECHNOLOGY CO., LTD (CN) | 2022-06-02 | — | — | US | disclosed |
| EP-4006025-A1 | HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE THEREOF | Changchun Hyperions Technology Co., Ltd. (CN) | 2022-06-01 | — | — | EP | disclosed |
| CN-112442023-B | Heterocyclic derivative and organic electroluminescent device thereof | 长春海谱润斯科技股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-112442023-A | Heterocyclic derivative and organic electroluminescent device thereof | 长春海谱润斯科技股份有限公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2007106503-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007106503-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070200490-A1 | Nitrogenous Heterocycle Derivative, And Organic Electroluminescent Element Employing The Same | IDEMITSU KASON CO.LTD (JP) | 2007-08-30 | — | — | US | disclosed |
| WO-2007061737-A2 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1734038-A1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20060147747-A1 | 2-[4-(10-naphthalene-2-yl-anthracene-9-yl)-phenyl]-1-phenyl-1H-benzimidazole; elevation of luminance and of efficiency in light emission even under low driving voltage | IDEMITSU KOSAN CO., LTD. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1602648-A1 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070200490-A1 | Nitrogenous Heterocycle Derivative, And Organic Electroluminescent Element Employing The Same | RPS3A, NCOA3, HNRNPA0 | ESR1 10/4885ESR2 41/4885SIRT2 2419/4885 |
| US-20220173333-A1 | HETEROCYCLIC DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE THEREOF | KCNH1, OCIAD2, ETFB | ESR1 330/4885ESR2 449/4885SIRT2 1172/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | ESR1 2744/4885ESR2 2259/4885SIRT2 2034/4885 |
| US-11665961-B2 | Heterocyclic compound and organic light emitting device using same | CRY1, CYP1B1, CRY2 | ESR1 319/4885ESR2 1073/4885SIRT2 2247/4885 |
| US-12297191-B2 | Heterocyclic derivative and organic electroluminescent device thereof | KCNH1, OCIAD2, ETFB | ESR1 330/4885ESR2 449/4885SIRT2 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.